Co-Phenylcaine Spray: can we improve the taste? A randomised, double-blind, crossover study. Issue 2 (7th July 2017)

• Record Type: Journal Article
• Authors: Bailey, S; Panizza, B; Cabot, P; Wallwork, B
• Is Part Of: Journal of laryngology & otology. Volume 132:Issue 2(2018)
• Page Start: 138
• Page End: 142
• Publication Date: 2017-07-07
• Subjects: Anesthetics, -- Local, -- Decongestants, -- Endoscopy, -- Nasal Mucosa; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1017/S0022215117001359
• Languages: English
• ISSNs: 0022-2151

Abstract

Abstract: Objective: Co-Phenylcaine Forte is a nasal spray routinely prescribed by otolaryngologists in Australia. The taste of Co-Phenylcaine Forte is typically described as unpleasant. This study sought to improve the overall patient experience associated with Co-Phenylcaine Forte by generating a Co-Phenylcaine Forte formulation, referred to as Co-Phenylcaine Zest, which contains an added vanilla flavour and masking agent. Methods: Participants were randomised to receive two actuations of Co-Phenylcaine Forte in each nostril followed by two actuations of Co-Phenylcaine Zest, or vice versa. There was a 6–36-hour washout period between each treatment. After the administration of each spray, participants completed a questionnaire to rate various sensory attributes of each formulation on seven-point ordinal scales. Patients reported their overall formulation preference after receiving both treatments. Results: A total of 86 participants completed the trial. Seventy-four per cent of patients preferred Co-Phenylcaine Zest, 21 per cent preferred Co-Phenylcaine Forte and 5 per cent had no preference ( p < 0.001). The satisfaction score associated with Co-Phenylcaine Zest was 1.22 points greater than with Co-Phenylcaine Forte ( p < 0.001). Conclusion: A novel formulation of Co-Phenylcaine Forte was created by adding a flavour and a masking agent; this formulation was preferred by most patients.